VANCOUVER, BC, Aug. 14, 2024 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended June 30, 2024. "This quarter we were proud to announce a significant milestone - Health Canada and US FDA authorization of a Phase II clinical trial studying PEX010 for methamphetamine use disorder," said Benjamin Lightburn, Chief Executive Officer and Co-Founder at Filament Health. "This is an important step to advancing our drug development efforts in substance use disorders, an area of significant unmet need for millions of people in North America, and globally. " Q2 2024 Financial Highlights: On June 12, 2024, the Company completed a private placement for gross proceeds of $135,000, received proceeds from the exercise of warrants for $864,222, and issued common shares pursuant to the conversion of a $1,250,000 convertible debenture. Cash and cash equivalents of $1,335,641 and a working capital of $579,519; Cash used in operating activities of $1,432,141; and total revenues of $407,640.  Q2 2024 Operational Highlights: